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Abstract. Gastric cancer is one of the most frequent malignancies in the world. Nonetheless, the knowledge of the molecular
events involved in the development of gastric carcinoma is far from complete. One of the hallmarks of gastric cancer is chromo-
somal instability resulting in abnormal DNA copy number changes throughout the genome. Mixed gastric carcinomas constitute
a rare histological entity, containing the two main histological phenotypes (diffuse and intestinal). Very little is known about
the underlying mechanisms of phenotypic divergence in these mixed tumours. To the best of our knowledge only E-Cadherin
mutations were implicated so far in the divergence of these tumours and nothing is known about the involvement of chromosome
copy number changes in the two divergent histological components. In this study, we compared the DNA copy number changes,
in the two different components (diffuse and intestinal) of mixed gastric carcinomas by microarray – comparative genomic
hybridisation (array CGH).
The analysis of 12 mixed gastric carcinomas showed no significant differences in array CGH profiles between the diffuse
and intestinal components of mixed carcinomas. This supports the idea that the phenotypic divergence within mixed gastric
carcinomas is not caused by DNA chromosomal aberrations.
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1. Introduction
Despite the overall decrease in incidence and mor-
tality rates, gastric cancer remains the second most fre-
quent malignancy worldwide [25,26]. Within the Eu-
ropean Union, incidence and mortality rates differ be-
tween countries, Portugal having the highest incidence
(31.9/100.000) and mortality (17.5%) rates attributable
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b.carvalho@vumc.nl.
to gastric cancer [2]. In contrast, in The Netherlands
gastric cancer ranks fifth as cause of cancer death [43],
with an incidence of 15.5/100.000 [2].
Two main histological types of gastric cancer are
recognized, the intestinal [22] or glandular carci-
noma [5] and the diffuse [22] or isolated-cell type car-
cinoma [5]. Distinct genetic pathways underlie these
two types of gastric cancer. Mutations in particular
genes are restricted to one of the two histological
types, such as mutations in CDH1 (the gene encod-
ing for the adhesion molecule E-cadherin) that occur
only in diffuse gastric carcinoma [1,10] or amplifica-
tion, and consequently over-expression, of the ERBB2
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oncogene, which is only observed in intestinal gastric
carcinoma [42].
In addition, there is a third histological type, the
mixed gastric carcinoma, with a dual pattern of dif-
ferentiation, encompassing in the same tumour dis-
tinct histological components (intestinal/glandular and
diffuse/isolated-cell type) [22,5]. Mixed gastric carci-
nomas have a poor prognosis and it was advanced that
this might be due to the cumulative effect of the ad-
verse characteristics of each of the constituents: blood-
born metastases for the intestinal/glandular component
and peritoneal dissemination with lymph node metas-
tases for the diffuse/isolated-cell component [5]. Sur-
vival of patients with mixed carcinomas was shown to
be significantly worse than that of patients with pure
histological type tumours [6].
Analysis of CDH1 mutations in a series of 26 gas-
tric carcinomas (10 “pure” intestinal, 10 “pure” dif-
fuse and 6 mixed carcinomas) showed that mutations
were found in diffuse carcinomas and, within mixed
carcinomas, were only detected in the diffuse com-
ponent of the tumours, thus providing a genetic basis
for the phenotypic divergence within mixed carcino-
mas [23].
Chromosomal instability is a hallmark of solid
tumours [8]. In gastric cancer, DNA copy number
changes constitute a major part of the genomic alter-
ations observed, and aberrations that are consistently
described by CGH are gains of chromosome 3q, 7p,
7q, 8q, 13q, 17q, 20p and 20q and losses 4q, 9p,
17p and 18q [29,11,41,17,49,12,47,28,18,34,45,20].
When comparing the copy number changes between
the two histological types, some authors found differ-
ences [19,42,49] while others observed similar patterns
of chromosomal copy number changes in both intesti-
nal and diffuse carcinomas [24,18,41,47].
Although rare, mixed gastric carcinomas constitute
an excellent model of nature to analyse within one tu-
mour the pattern of copy number changes of two di-
verging histological types, i.e. intestinal and diffuse.
To the best of our knowledge, this is the first study
that analyses DNA copy number changes in the two
distinct components (intestinal and diffuse) of mixed
gastric cancers by array CGH.
2. Materials and methods
2.1. Sample collection and DNA isolation
Twelve formaldehyde-fixed, paraffin-embedded gas-
tric carcinoma tissue samples, classified as mixed car-
cinomas (containing distinct areas of intestinal and dif-
fuse components) were collected. Nine cases origi-
nated from Hospital S. João, Porto, Portugal, two cases
from the Dutch D1/D2 trial [3] and one case from
the Academic Unit of Pathology, University Leeds,
United Kingdom. All samples analysed showed metas-
tasis in the lymph nodes at time of diagnosis and were
therefore considered advanced tumours. From these
cases, areas containing at least 70% tumour cells in
each component were selected on a 4 µm haema-
toxylin and eosin stained tissue section, by a pathol-
ogist (G.A.M.). Adjacent serial sections of 10 µm
were cut for DNA isolation and a final 4 µm haema-
toxylin and eosin stained section was made as con-
trol, to check whether there was still tumour in the
marked area. After deparaffination with xylene, the ar-
eas corresponding to each component were carefully
scratched from the slide with a scalpel blade. DNA
was isolated as previously described [44] using a com-
mercially available column-based method (QIAamp
DNA isolation mini kit; Qiagen, Westburg, Leusden,
The Netherlands). For very small tissue samples a mi-
crokit was used (QIAamp DNA isolation microkit; Qi-
agen, Hilden, Germany). DNA concentrations were de-
termined using Nanodrop ND-1000 spectrophotome-
ter (Isogen, IJsselstein, NL). DNA quality for array
CGH was assessed by performing PCR for the hu-
man housekeeping gene β-globin using two primer sets
that produce 209 bp (β3 forward primer acacaactgt-
gttcactagc and β5 reverse primer gaaacccaagagtcttctct)
and 300 bp (β3 forward primer acacaactgtgttcactagc
and β6 reverse primer catcaggagtggacagatcc) prod-
ucts. Of each archival sample, 50 ng DNA in a fi-
nal volume of 5 µl was added to a PCR mixture con-
taining 1.5 mM MgCl2, 0.2 mM dNTPs, 0.5 U Taq
DNA polymerase (Applied Biosystems, Nieuwerkerk
aan den IJssel, NL), 0.5 µM forward primer (β3) and
0.5 µM reverse primer (either β5 or β6). PCR reac-
tion was performed for 40 cycles (1 minute at 94◦C,
2 minutes at 58◦C, 1 minute 30 seconds at 72◦C) with
an initial denaturation of 4 minutes at 94◦C and a fi-
nal extension 4 minutes at 72◦C. Human DNA from
placenta and water were used as positive and nega-
tive control, respectively. PCR products were visual-
ized on a 2% agarose ethidium bromide-stained gel.




We used a full-genome BAC array printed in the
house containing approximately 5000 DNA clones
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(http://www.vumc.nl/microarrays/index.html). The ar-
ray comprised the Sanger 1 Mb clone set with an av-
erage resolution along the whole genome of 1.0 Mb
(http://www.ensembl.org/Homo_sapiens/cytoview),
the OncoBac set (http://informa.bio.caltech.edu/Bac_
onc.html), containing approximately 600 clones cor-
responding to 200 cancer-related genes, and selected
clones of interest obtained from the Children’s Hospi-
tal Oakland Research Institute (CHORI) (http://bacpac.
chori.org/home.htm), to fill any gaps larger than 1 Mb
on chromosome 6 and to have full-coverage contigs
of regions on chromosomes 8, 11, 13 and 20. Am-
plification of BAC clone DNA was done by ligation-
mediated polymerase chain reaction (PCR) according




Roosendaal, NL) at a concentration of 1 µg/µl, in
150 mM sodium phosphate, pH 8.5, using a SpotAr-
ray72 printer (Perkin Elmer Life Sciences, Zaventem,
BE). After printing, slides were processed according to
the manufacturers protocol (Codelink
TM
slides; Amer-
sham BioSciences, Roosendaal, NL).
2.2.2. Labelling and hybridisation
Array CGH was performed according to Snijders et
al. [31], with a few modifications. Briefly, 300 ng of
tumour and reference DNAs were labelled by random
priming (Bioprime DNA Labeling System, Invitrogen,
Breda, NL). Removal of unincorporated nucleotides
was done with sephadex columns (ProbeQuant G-50
Micro Columns – Amersham BioSciences, Roosen-
daal, NL). Cy3 labelled test genomic DNA and Cy5
labelled reference DNA were combined and co- pre-
cipitated with 100 µg of human Cot-1 DNA (Invitro-
gen, Breda, NL) by adding 0.1 volume of 3 M sodium
acetate (pH 5.2) and 2.5 volumes of ice-cold 100%
ethanol. The precipitate was collected by centrifuga-
tion at 14,000 rpm for 30 minutes at 4◦C. After air-
drying the pellet was dissolved in 130 µl hybridisa-
tion mixture containing 50% formamide, 2 × SCC,
10% dextran sulfate and 4% SDS. The DNA samples
were denatured for 10 minutes at 73◦C followed by
a 60 minutes incubation at 37◦C to allow the Cot-
1 DNA to block repetitive sequences. The array was
incubated for 38 h at 37◦C with the denatured and
blocked hybridisation mixture in a hybridisation sta-
tion (HybArray12
TM
– Perkin Elmer Life Sciences, Za-
ventem, BE). After hybridisation, slides were washed
in a solution containing 50% formamide, 2 × SCC,
pH 7 for 3 minutes at 45◦C, followed by 1 minute
wash steps at room temperature with PN buffer (PN:
0.1 M sodium phosphate, 0.1% nonidet P40, pH 8),
0.2 × SSC, 0.1 × SCC and 0.01 × SCC. Slides were
dried by centrifugation at 1000 rpm for 3 min at room
temperature.
2.2.3. Image acquisition, feature extraction and
normalization
Images of the arrays were acquired by scanning (Ag-
ilent DNA Microarray scanner – Agilent technologies,
Palo Alto, USA) and Imagene 5.6 software (Biodiscov-
ery Ltd, Marina del Rey, California) was used for auto-
matic feature extraction (segmentation of the spots and
quantification of the signal and background intensities
for each spot for the two channels Cy3 and Cy5). A mi-
crosoft Excel sheet was used to subtract local back-
ground from the signal median intensities of both test
and reference DNA and to calculate the tumour to ref-
erence ratios. Test to normal fluorescence ratios were
normalized against the mode of the ratios of all auto-
somal clones. As the clones were spotted in triplicate,
the median value of the corresponding three intensities
was used for each clone in the array. If the standard de-
viation of the intensity of the three spots was greater
than 0.2, clones were excluded from further analysis.
Furthermore, clones with more than 20% missing val-
ues in all carcinomas were also excluded from further
analysis.
All subsequent analyses were done considering the
clone position from the UCSC May 2004 freeze of the
Human Golden Path.
2.3. Data analysis
2.3.1. DNA copy number segmentation
To segment DNA copy number alterations (gains
and/or losses), a smoothing algorithm – “aCGH-
Smooth” was applied [14,15] (http://www.few.vu.nl/
∼vumarray/). Because there was variation of the level
of noise between experiments, different cut-offs for
calling gains and losses were used. To establish the
most appropriate threshold in each experiment, the
standard deviation (SD) computed in every case over
an area without aberrations was used as input for a vari-
able in the Array CGH Smooth (using default settings)
that determines the cut off for gains and losses. Ampli-
fication was considered when the ratio (in a logarith-
mic scale) was above 1.0.
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2.3.2. Statistical analysis
Statistical analysis comparing the intestinal and dif-
fuse components from the same tumour was done us-
ing CGHMultiArray [40] adapted for paired analysis
by using the Wilcoxon signed-rank test corrected for
ties. A false discovery rate (FDR) of <0.1 was re-
garded as statistically significant. All the analyses were
done excluding chromosomes X and Y, as in every hy-
bridisation a sex-mismatched reference DNA was used
for quality control of the experiment.
3. Results
We studied 12 gastric cancers of mixed histologi-
cal type, by array CGH, analysing separately the two
components (intestinal and diffuse). The mean num-
ber of aberrations observed per tumour was 10.22
(range 3–21). Overall, gains were more frequent than
losses, on average the number of gains observed per tu-
mour was 7.22 (1–16) compared to an average number
of losses of 3.00 (0–12). Figure 1 gives an overview
of the frequency of gains and losses in both intesti-
nal and diffuse components of the mixed gastric can-
cers analysed. The most frequent aberrations (>20%;
at least in 2 cases) observed in both components were
gains on chromosomes 1, 6p, 7, 8, 10, 11, 12p, 13q,
16, 17q, 19q, 20 and 22q, and losses on chromo-
some 9p. We detected amplifications in four cases, on
chromosome 8p, 8q, 12p, 15q, 17q and 20q (Table 1).
On chromosomes 8p and 15q the amplified regions
were large, spanning segments of approximately 7 and
11 Mb, respectively. Nevertheless, these regions in-
clude the genes SOX7 and CTSB (Cathepsin B) on 8p
and IQGAP1 on 15q which are known to be overex-
pressed/amplified in gastric cancer. The amplification
observed on 8q spans a region of 3.9 Mb and con-
tains 7 genes (TRMT12, RNF139, TATDN1, MTSS1,
TRIB1, FAM84B and c-MYC). The genes K-RAS, and
ERBB2 map to the amplified regions detected in 12p
(RP11-707G18), and 17q (RP11-94L15), respectively.
On chromosome 20q, two known cancer-related genes
map in the amplified region, ZNF217 and CYP24A1.
Examples of amplifications can be seen in Figs 2A
and B. In all amplicons, the amplified clones harbour-
ing these genes were exactly the same in both histolog-
ical components. As illustrated in Fig. 2B, both intesti-
nal and diffuse components of case #1 have the same
amplified clone on 17q (RP11-94L15), which harbours
the oncogene ERBB2.
3.1. Comparison between the two components
When comparing the intestinal and diffuse compo-
nents by means of CGH MultiArray for paired sam-
ples, we did not find any statistically significant dif-
ference between the intestinal and the diffuse com-
ponent for every clone throughout the whole genome
(Fig. 3). In addition, in order to identify and high-
light any DNA copy number changes that differed be-
tween the two components, we calculated the ratio of
the DNA copy number log 2 ratios from both compo-
nents, diffuse versus intestinal [Log2 (ratio D1/I1) =
log 2 (ratio D1) − log 2 (ratio I1)]. As expected these
ratios were close to zero (Fig. 4), with the exception of
a few cases with higher noise levels (Fig. 5).
4. Discussion
DNA copy number changes have been suggested
to underlie some biological processes within tumours,
such as metastisation [7,4,21] and acquisition of drug
resistance [39]. We hypothesised that DNA copy
changes might also underlie the phenotypic divergence
observed in mixed gastric carcinomas. To address this
hypothesis we studied 12 mixed gastric carcinomas by
array CGH and analysed separately the distinct com-
ponents (intestinal and diffuse) of each tumour.
In the present study, copy number changes were
found on chromosomes 1, 6p, 7, 8, 10, 11, 12p, 13q,
16, 17q, 19q, 20 and 22q (gains) and 9p (losses).
In 4 cases we found also amplifications, affecting
chromosomes 8pq, 12p, 15q, 17q and 20q. Map-
ping to these regions there are genes which were de-
scribed in literature to be amplified and/or overex-
pressed in gastric cancer [29,20,37,30,48,46,33,16,9].
These genes include: SOX7 (8p23.1), CTSB (8p23.1),
C-MYC (8q24.12-q24.13), K-RAS (12p12.1), IQGAP1
(15q26.1), ERBB2 (17q21.1), ZNF217 (20q13.2) and
CYP24A1 (20q13.2). Although in some amplicons
only one gene is present, being the obvious candidate
to drive the amplicon, like K-RAS on 12p12.1, in other
amplicons, where the region is larger, it is more dif-
ficult to pinpoint a single candidate responsible for
driving the amplicon, like SOX7 and/or Cathepsin B
(CTSB) on 8p23.1. Also, the amplification on 8q har-
bours several known genes besides c-MYC, like TRIB1
and FAM84B. Indeed in haematological malignancies
as well as in oesophageal cancer some data exclude c-
MYC as driving gene in 8q amplification in favour of
either TRIB1 [32] or FAM84B [13].
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Fig. 1. Frequencies of gains and losses throughout the genome in all analysed tumours. (A) Diffuse-type component; (B) Intestinal-type compo-
nent. Clones are sorted by position per chromosome (1-X). Vertical lines – transition between chromosomes; Dashed-vertical lines – centromere
position.
288 B. Carvalho et al. / Mixed gastric carcinomas show similar chromosomal aberrations in both their diffuse and glandular components
Fig. 2. Two cases with amplification of specific genomic regions. Case #7 present an amplification on chromosome 8q (A) and case #1 on
chromosome 17q (B). Black squares-smoothed ratios. Two vertical lines – centromeric region.
Table 1
Mixed gastric carcinomas with one or more amplified regions
Case nr. Chromosome Mb location Size amplicon (Mb) Possible candidate genesa
1 17q 37.9–38.5 0.65 ERBB2
4 8p 4.3–11.7 7.4 SOX7, CTSB
7 8q 125.5–129.4 3.9 TRIB1, FAM84B, C-MYC
15q 88.1–99.9 11.8 IQGAP1
20q 49.9–52.2 2.3 ZNF217, CYP24A1
10 12p 25.3–25.7 0.4 K-RAS
aIn bold, oncogenes known to be amplified in gastric cancer.
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Fig. 2. (Continued).
No statistically significant differences were found
between the intestinal and diffuse components within
the same tumour samples. Based on the results we ob-
tained we would expect that the ratio between the two
components’ ratios within the same tumour should be
one, or zero in a logarithmic scale. In keeping with this
hypothesis, when we subtracted the log 2 ratios we ob-
tained a ratio close to zero. Our findings are in agree-
ment with earlier observations in bladder tumours with
mixed histology, analysed by chromosome CGH, in
which a high level of concordance was found also for
samples within one tumour with different histological
components [36].
By CGH on 46 primary tumours, we did not find
differences in copy number changes between pure in-
testinal and diffuse carcinomas [41]. Our results within
mixed gastric carcinomas are in keeping with these
findings. These observations suggest that the mecha-
nism underlying the intestinal and diffuse histotypes of
gastric cancer (within mixed or pure carcinomas) is not
caused by DNA copy number changes but by other bi-
ological events, like mutation and/or promoter hyper-
methylation, not detectable by array CGH.
In some cases, small quantitative differences were
observed in some chromosomal regions, specifically
on chromosomes 8 and 20. In those cases the genomic
profile of both components was similar but the aber-
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Fig. 3. Graphic view of the p-values obtained in the paired analysis where the two components (intestinal and diffuse) were compared in each
tumour.
Fig. 4. Examples of ratios between diffuse and intestinal components within the same tumour (Log2 ratio Diffuse – Log2 ratio Intestinal).
Dashed-vertical lines – transition between chromosomes.
rations in the intestinal component were more pro-
nounced (higher ratios in the gained regions and lower
ratios in the lost regions) when compared to the diffuse
component (Figs 2A and 5B). Most probably, these
differences are due to the higher amount of stromal
cells in the diffuse component lowering the ratio tu-
mour/normal reference.
Although we are assuming that the copy number
changes observed are cancer specific, we can not ex-
clude the possibility that some of these changes might
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Fig. 5. DNA copy number changes profiles of two mixed gastric cancers, one with high level of noise, (A) case #4, and one with low level of
noise, (B) case #7; intestinal and diffuse components analysed separately. Vertical lines – transition between chromosomes.
represent polymorphisms, which to some extent could
contribute to similarities in the patterns of chromo-
somal aberrations seen in matched samples (i.e. the
intestinal and diffuse components within a single tu-
mour).
Some of the gains and losses observed in this study
were detected in regions which are consistently altered
in gastric cancer, such as losses on 9p, gains on 7,
8q, 13q, 17q and 20 [34,49,18,41,20,29,11,17,28,12,
45]. Other changes, such as gains on 1p, 6p, 11, 12p,
16, 19q and 22q, which were frequently detected in
our study are also described in literature, although less
frequently [49,34,24,35,27]. However, other chromo-
somal aberrations like 18q loss, that frequently oc-
cur in gastric carcinoma, were very rare or absent in
this series of mixed gastric carcinomas [29,12]. This
could be explained by the small sample size, that is a
consequence of the low incidence of these lesions, al-
though we can not rule out that mixed gastric carcino-
mas may show different patterns of chromosome aber-
rations compared to the pure histological types.
Kokkola and collaborators [19] detected amplifica-
tions of 17q only in (pure) intestinal-type gastric car-
cinomas. In our series of mixed gastric carcinomas we
found in one case that both components harboured 17q
amplification, with the same clone being involved in
both components (Fig. 2B). This finding suggests a
clonal origin for mixed gastric carcinomas (or at least
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Fig. 5. (Continued).
for this tumour). According to Machado and collab-
orators [23], mutations of CDH1 gene constitute the
genetic basis for the phenotypic divergence of mixed
gastric carcinomas. Our results suggest that after this
event, no substantial DNA copy number changes take
place.
In summary, in the analysis of 12 mixed gastric car-
cinomas by array CGH, we found the copy number
changes that have been consistently reported in the lit-
erature in gastric carcinomas and, within each tumour,
we found similar profiles in both components. Our re-
sults support the idea that mixed gastric carcinomas are
clonal and the phenotypic divergence is not caused by
chromosomal aberrations.
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